US4499084 Patent Landscape and Claim-Strength Analysis for DMSO/Water Anti-HSV Topical Formulations Using Ara-A (Acyclovir/Ribavirin Alternatives)
US Patent 4,499,084 claims a topical herpes simplex virus (HSV) treatment that uses a solvent carrier translocating through the body and penetrating cell walls comprised of dimethyl sulfoxide (DMSO) and water, combined with an antiviral agent that interferes with viral DNA synthesis to inhibit viral maturation, where the antiviral is ara-A (adenine arabinoside, vidarabine) and, in dependent scope, purine analogs of ara-A selected from acyclovir and ribavirin. The patent is claim-dense around (i) carrier function and composition, (ii) ara-A/purine-analog selection, and (iii) application frequency (every 2 to 4 hours) plus optional local anesthetic and gel-forming agent.
Below is a critical analysis of what is actually protected, where the claim scope is likely narrow or vulnerable, and how the landscape around HSV antivirals, DMSO penetration, and topical formulation patents would affect enforcement and design-around.
What does US 4,499,084 protect for herpes simplex virus (HSV) treatment?
Core protected subject matter
US 4,499,084 protects two main categories:
-
Antiviral composition (Claim 1) for treating HSV disease in humans:
- Carrier: a solvent carrier “will translocate throughout the body and penetrate cell walls”
- Carrier composition: includes DMSO and water
- Antiviral agent: ara-A
- Mechanism language: interferes with viral DNA synthesis, inhibiting viral maturation
-
Topical treatment method (Claim 2 and dependents):
- Administration: topically apply to infected portions every 2 to 4 hours
- Product: the same DMSO/water carrier plus the same antiviral agent (ara-A)
- Dependents add local anesthetic (Claim 3) or gel-forming agent (Claim 4)
Purine-analog substitution scope
Claims 5 and 6 expand the antiviral component beyond ara-A to a set: “purine analog of ara-A” selected from acyclovir and ribavirin. In other words, the patent is not only about ara-A, it also tries to rope in a narrower, defined family of HSV antivirals.
Percent/weight formulation constraining claims
Claims 7-8 and 10-11 lock down additional commercializable specificity:
- Ara-A amount: 0.1 to 10.0% by weight
- DMSO in solvent carrier: 50% up to less than 100% (or 50-100% in later claim language)
- Water (demineralized water): 0-50% range depending on the claim
- Example composition: 1.0 g ara-A / 70.0 mL DMSO / 30.0 mL water
Claim mapping (what an accused product must show)
| Claim element |
What accused product would need |
| HSV indication |
Labeled for HSV treatment or used for HSV disease |
| Topical administration |
Must be a topical application regimen (claims 2-4) |
| Frequency |
Every 2 to 4 hours (method claims) |
| Solvent carrier function |
“Translocate throughout the body” and “penetrate cell walls” language can be argued as product capability and/or intended effect |
| Carrier composition |
Must include DMSO + water |
| Antiviral selection |
Must include ara-A (claims 1-4) or, for claims 5-6, must include acyclovir or ribavirin as “purine analogs” |
| Mechanism language |
DNA synthesis interference and inhibition of viral maturation (often intrinsic to the antiviral MOA) |
| Optional components |
Local anesthetic (claim 3) and/or gel-forming agent (claim 4) |
| Quantitative ranges (if used) |
Matching % wt or example composition (claims 7-8, 10-11) |
How broad are the claims on carrier “translocate throughout the body” and “penetrate cell walls”?
The carrier function language is the patent’s primary attempt to broaden beyond “mere solvent” into a functional penetrant/transport claim.
Risk point: functional language can be used against the patentee in claim construction
The phrases:
- “will translocate throughout the body”
- “penetrate cell walls”
are not expressed as a measurable parameter (e.g., flux, tissue distribution, permeability coefficient) in the claim text you provided. That creates two practical enforcement pressure points:
- Proof burden in litigation: an accused infringer can argue that its formulation does not achieve the claimed functional outcomes, or that the language is aspirational/therapeutic result rather than a composition feature.
- Design-around options: competitors can keep DMSO but limit “penetration” effect by changing solvent system structure, viscosity, occlusion, penetration inhibitors, or formulation form factor, aiming to avoid the functional territory.
What is likely more enforceable: DMSO + water as a compositional limitation
The carrier composition element is clear and objective: it must include DMSO and water. That is harder to evade than functional phrasing.
Practical bottom line
- If a generic or competitor makes a DMSO-water topical antiviral formulation, they are closer to the literal “solvent carrier includes DMSO and water” limitation.
- The functional language can still become a litigation lever, especially for products that use DMSO but do not claim or evidence “translocation throughout the body” or “cell wall penetration” in a comparable way.
Which antiviral agents does US 4,499,084 cover: ara-A vs acyclovir vs ribavirin?
Claims 1-4 (ara-A)
- Antiviral agent is ara-A.
- The mechanism is DNA synthesis interference and inhibition of viral maturation, which aligns with established purine analog antiviral activity.
Claims 5-6 (purine analogs of ara-A)
- Antiviral agent is a purine analog of ara-A
- Selected from: acyclovir and ribavirin
Critical issue: scope depends on claim construction of “purine analog of ara-A”
This is a defined set, but it is still a patent-law construction question:
- Are acyclovir and ribavirin treated as “purine analogs” as understood in medicinal chemistry?
- If yes, that portion becomes less vulnerable.
- If argued narrowly, a defendant could contest whether the “purine analog of ara-A” limitation restricts to specific structural criteria, even though acyclovir and ribavirin are explicitly named.
Enforcement consequence
Because the claim names acyclovir and ribavirin as the permitted options, a defendant using either generally faces higher literal risk than if the claim only said “purine analogs,” leaving identity open. Still, the “selected from the group consisting of” language means only those named actives would be within that branch.
What formulations are protected: DMSO-water topical compositions and percent by weight constraints?
Composition claims without numerical ranges
- Claim 1 and Claim 5 do not require explicit % ranges. They only require:
- DMSO and water in the solvent carrier
- ara-A (or the defined purine analogs) as the antiviral agent
Composition claims with numerical constraint
- Claim 7 adds weight % boundaries:
- ara-A: 0.1 to 10.0%
- DMSO: 50% to <100% of the solvent carrier
- demineralized water: >0% up to 50%
- Claim 8 gives a concrete approximate formulation:
- 1.0 g ara-A
- 70 mL DMSO
- 30 mL demineralized water
Method-side numerical constraints
- Claim 10 parallels Claim 7 but allows water 0 to 50% and DMSO 50 to 100% of the solvent carrier.
- Claim 11 repeats the example formulation amounts.
Practical inference for infringement vs invalidity posture
- If an accused product uses ara-A plus DMSO and water but outside the stated ranges, it may still fall under Claims 1/2/9 rather than the narrower quantitative claims.
- If it uses an acyclovir/ribavirin branch with DMSO + water, it hits Claims 5/6.
- A competitor could try to avoid infringement by changing the carrier to exclude water entirely, exclude DMSO, or use a different solvent system while staying topical and antiviral.
Does the patent protect topical dosing frequency “every 2 to 4 hours”?
Yes, method claims 2 and 6 are frequency-specific
- Claim 2: topically apply every two to four hours
- Claim 6: same regimen for acyclovir/ribavirin branch
Why this matters
- Frequency is a concrete regimen limitation. If a product label or instructions use a different interval (e.g., twice daily), method infringement risk can decrease.
- Composition claims (like Claim 1 and 5) do not include dosing frequency. That means the formulation itself might still be implicated even if dosing frequency is modified.
Critical enforcement point
A defendant can reduce exposure by:
- marketing and instructing different dosing intervals,
- while still selling a composition that might remain vulnerable under composition claims.
So dosing-frequency design-around is more effective for method claims than composition claims.
How do optional components change claim scope: local anesthetic and gel-forming agent?
Claim 3
- Adds a local anesthetic on top of Claim 2’s DMSO/water + ara-A and frequency regimen.
Claim 4
- Adds a gel-forming agent.
Litigation implication
These are narrower dependents. In an infringement dispute, defendants can focus on:
- omitting local anesthetic (avoiding Claim 3),
- omitting a gel-forming component or using a formulation classified differently (avoiding Claim 4),
while still potentially remaining in range of Claim 2.
What is the likely US patent landscape relevance around DMSO-enhanced topical antivirals for HSV?
US 4,499,084 sits at the intersection of:
- antiviral nucleoside analog therapy for HSV,
- solvent/penetration enhancer approaches, especially DMSO in topical settings,
- and formulation/application regimen claims.
Landscape impact categories that typically collide with this patent’s claim elements
- Antiviral molecule IP: ara-A (vidarabine) and later HSV nucleoside analogs such as acyclovir and related agents have their own composition and method of use IP histories.
- DMSO penetration enhancer formulation IP: penetrant/transdermal-style formulation patents and topical delivery enhancer patents frequently overlap “DMSO + active + topical dosing” territory.
- HSV therapeutic method patents: additional method-of-use claims for HSV dosing regimens and vehicle types may exist, affecting freedom to operate even if US4499084 is not the dominant patent.
Because your request is explicitly about claims and the patent landscape, the key analytic point is structural: US4499084 is not claiming the antiviral nucleoside generically; it is claiming a specific delivery vehicle logic (DMSO + water with functional translocation/penetration) and specific topical regimen (2-4 hour interval) plus specific actives (ara-A and named purine analogs).
That means later entrants often use:
- different carriers (propylene glycol, ethanol/water, liposomes, emulsions),
- different dosage forms (cream vs gel vs solution),
- different penetrants (without DMSO or with modified solvent packages),
- different dosing schedules.
When would US 4,499,084 lose exclusivity, and what does that mean for current generic risk?
If US 4,499,084 is evaluated under the typical US term framework for patents issued in the late 20th century, exclusivity would have expired long ago in practical markets. The key business consequence is that:
- the patent is mainly relevant for historical clearance, archival Freedom-to-Operate work, and litigation involving legacy or infringing conduct during term,
- not for current commercial exclusivity barring routine formulation development, unless there were intervening continuations, reissues, or later patents in the same family.
Because the prompt does not provide the filing date, priority date, or maintenance/term computations, a precise “expiration date” cannot be stated from your supplied information.
How strong is US 4,499,084 as an enforcement asset?
Strengths
- Clear and objective compositional limitation: DMSO + water.
- Clear antiviral identity for main branch: ara-A.
- Clear antiviral identity for dependent branch: acyclovir and ribavirin are explicitly named as “purine analogs of ara-A.”
- Method claims include a concrete dosing interval: every 2 to 4 hours.
- Additional dependent narrowings (local anesthetic, gel-forming agent) give multiple claim targets, enabling settlement leverage.
Weaknesses
- Functional carrier language (“translocate throughout the body,” “penetrate cell walls”) can create claim-construction and proof problems.
- Functional “viral maturation inhibition” language is mechanism-based and may be treated as inherent to the drug’s known MOA rather than a differentiating formulation attribute.
- The patent is vulnerable to obviousness-type arguments in a landscape where:
- DMSO as a penetration enhancer is well established,
- HSV nucleoside analogs have known MOAs,
- combining an established penetration enhancer with an established antiviral nucleoside in a topical regimen can be attacked as routine optimization.
Litigation leverage profile
A patentee would likely anchor infringement on the DMSO + water + ara-A (or DMSO + water + acyclovir/ribavirin) elements and use method claims only if the defendant’s regimen matches 2-4 hour topical application and optional features match dependents.
What generic entry risks exist for DMSO/water ara-A or acyclovir/ribavirin HSV topical products?
Given US4499084’s specific claim structure, risk hinges on whether a product:
- Uses DMSO and water together in the topical carrier
- Contains ara-A (or acyclovir/ribavirin in the purine analog dependent branch)
- Matches (for method claims) topical application every 2 to 4 hours
- Adds local anesthetic or gel-forming agent if asserting dependents
For current product development, the practical generic risk analysis tends to be dominated by:
- whether there are newer, still-live patents in the relevant families (formulation, method-of-use, penetrant systems, stability, device/form factors),
- and whether regulatory labeling or clinical instructions replicate the claimed regimen.
US4499084’s claim specificity reduces its chance of covering broadly all “DMSO topical HSV treatments”; it is aimed at a particular formulation logic and schedule. That usually narrows infringement scope relative to patents that claim “topical antiviral compositions comprising any penetration enhancer.”
How do patents like US 4,499,084 compare with modern HSV topical delivery and MOA claim strategies?
Modern patenting for topical antivirals usually shifts toward:
- specific delivery systems: emulsions, nanoemulsions, liposomes, polymeric films, mucoadhesive systems,
- specific permeability or tissue delivery metrics,
- specific excipient sets and controlled-release mechanisms,
- specific patient/lesion use instructions aligned to clinical endpoints.
US4499084 is more “vehicle-and-schedule” oriented:
- DMSO + water carrier with asserted penetration/translocation,
- and frequent topical dosing.
That makes the patent’s enforceability dependent on whether an accused product still uses that classic DMSO-water approach and matches dosing frequency.
Key takeaways
- US 4,499,084 protects topical HSV antiviral compositions where the carrier is DMSO + water and the antiviral agent is ara-A (primary) with a dependent branch extending to acyclovir or ribavirin as “purine analogs of ara-A.”
- Method claims add a concrete regimen: topical application every 2 to 4 hours, plus optional narrowing for local anesthetic and gel-forming agent.
- Claim scope strength is anchored in objective limitations (DMSO + water, named actives) and weakened by functional carrier language (“translocate throughout the body,” “penetrate cell walls”), which can be contested on construction and proof.
- For commercial risk today, the business relevance is usually more about historical or legacy FTO and litigation posture than active exclusivity, absent confirmation of current patent term status or family continuations.
FAQs
-
If a product uses DMSO but no water, does it avoid US 4,499,084?
It avoids the “solvent carrier includes dimethyl sulfoxide and water” limitation under Claims 1 and 5, and the corresponding method claims requiring the same carrier.
-
Does US 4,499,084 cover acyclovir-only formulations without ara-A?
Yes, under the dependent branch (Claims 5-6) that allows acyclovir as a named “purine analog of ara-A,” assuming the DMSO-water carrier and mechanism language are met.
-
Can changing dosing frequency defeat infringement of the method claims?
It can reduce or avoid method infringement risk because Claims 2 and 6 specify “every two to four hours.” Composition claims may still remain exposed.
-
What role do gel-forming agents and local anesthetics play in claim coverage?
They create narrower dependent coverage under Claims 3 and 4. Products omitting those components can still fall under broader independent claims if they match the DMSO-water + antiviral limitations.
-
Is the antiviral mechanism language a distinguishing claim limitation?
It is mechanism-based, but enforcement often hinges more on the identity of the antiviral and the carrier composition than on proving the claimed biological “inhibits viral maturation” effect as an additional independent differentiator.
References (APA)
- United States Patent 4,499,084. “Antiviral composition for treating herpes simplex virus disease in humans.” Claims provided in prompt.
